Thus, Pim-1 and Pim-2 may play indistinguishable and redundant roles in enhancement of the mTORC1 pathway in FLT3-ITD-expressing cells, which suggests that pan-Pim inhibitors should give more effective therapeutic effects against FLT3-ITD-positive AML than many Pim-1-selective inhibitors currently under development [23, 24]. The gene discussed is PIM2; the disease is acute myeloid leukemia.